Therapeutic Misconception in ALS

Event Description
Some subjects who participate in trials of novel therapies mistakenly believe that the trial is designed to maximize benefit to the individual subjects — thus laboring under the Therapeutic Misconception. Patients with ALS have a uniformly fatal disease, and some worry that ALS patients are even more prone to the therapeutic misconception.
Our speakers will discuss the evidence for a therapeutic misconception in ALS trials, and consider more broadly how the therapeutic misconception should be addressed by investigators and institutional review boards.
Speakers
Ways to Join
This event is free and open to the public, but if you are not affiliated with Harvard you must register to attend. Please bring proof of ID to the event due to building security. REGISTER NOW!
Twitter: Follow @HMSbioethics on Twitter and join the conversation using #neuroethx
Can’t attend in person? Watch the webcast live on bioethics.hms.harvard.edu.
Neuroethics Seminar Series
This event is part of a series hosted by the Center for Biothics at Harvard Medical School. For more information, visit the website.